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as obesity, may inﬂuence cardiac phenotypic and clinical course in patients with HCM.Methods In 275 adult HCM patients (age 48  14 years; 70% male), we assessed the relation of BMI to LV mass, determined
by cardiovascular magnetic resonance (CMR) and heart failure progression.Results At multivariate analysis, BMI proved independently associated with the magnitude of hypertrophy: pre-obese
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(BMI<25 kg/m2; hazard ratio [HR]: 1.65; 95% conﬁdence interval [CI]: 0.73 to 3.74, p¼ 0.22 and 3.1; 95% CI: 1.42
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(NYHA) functional class III to IV symptoms compared to nonobese patients, independent of outﬂow obstruction.
Noticeably, the proportion of patients in NYHA functional class III at the end of follow-up was 13% among obese
patients, compared with 6% among those of normal weight (p ¼ 0.03).Conclusions In HCM patients, extrinsic factors such as obesity are independently associated with increase in LV mass and may
dictate progression of heart failure symptoms. (J Am Coll Cardiol 2013;62:449–57) ª 2013 by the American
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12; revised manuscript received March 3, 2013,unexplained (1–5). In the vast majority of genotype-positive
patients, HCM is associated with mutations in genes
encoding proteins of the cardiac sarcomere, most commonly
beta-myosin heavy chain and myosin-binding protein C
(1–3). While these molecular defects are considered
responsible for the development of LVH, there is currently
no conclusive evidence to explain the variability in pheno-
typic expression of HCM, ranging from massive degrees to
absence of LVH even within the same family (1,4–6).See page 458Among several hypotheses, the interplay of modiﬁer genes
and environmental factors has been commonly offered as
a potential explanation for phenotypic diversity (7,8). To date,
however, the possibility of an environmental modulation of
the HCM phenotype remains speculative, and even the impact
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450of an obvious candidate variable
such as obesity, known to pro-
mote LVH in the general pop-
ulation, is unresolved (9–15). In
addition, it is unknown whether
the adverse metabolic and hemo-
dynamic effects of obesity, to
which HCM patients may be
exposed during the long-term
course of their disease, ultimately
affect symptomatic status and
prognosis (11,12,16–18). There-
fore, the present study was
designed, in a consecutive multi-
center cohort studied with cardiac
magnetic resonance (CMR), toassess the impact of body mass index (BMI) on the phenotype,
as well as clinical course, of HCM.Methods
Study population. The study cohort comprised 275 adult
patients with HCM (age >18 years, mean 48  14 years at
study entry; 70% male, maximum left ventricular (LV) wall
thickness 21  5 mm) consecutively referred for CMR
studies between January 2005 and June 2008 at 3 partici-
pating referral centers in the United States and Italy: Min-
neapolis Heart Institute Foundation (Minneapolis,
Minnesota; n ¼ 168); Tufts Medical Center (Boston,
Massachusetts; n ¼ 45); and Careggi University Hospital
(Florence, Italy; n ¼ 62). Diagnosis of HCM was based on
2-dimensional echocardiographic evidence of a hypertro-
phied, nondilated LV (maximal wall thickness 15 mm), in
the absence of another cardiac or systemic disease that could
produce the magnitude of hypertrophy evident (1,3). We
excluded signiﬁcant atherosclerotic coronary artery disease
(>50% stenosis in a major artery) by virtue of 2 speciﬁc
clinical or CMR criteria: 1) no study patient experienced an
acute coronary event associated with increased cardiac
enzymes or Q waves on electrocardiogram; and 2) in all
patients with late gadolinium enhancement (LGE) distrib-
uted in a single coronary vascular territory, hemodynamically
signiﬁcant coronary artery disease was excluded by arteriog-
raphy or computed tomography angiogram. Furthermore,
patients with prior cardiac surgery (including septal myec-
tomy), alcohol septal ablation, and chronic renal failure were
excluded (3). The study protocol was approved by the
respective Internal Review Boards or research ethics
committees of each institution, and written inform consent
was obtained from each subject.
Deﬁnitions. Body mass index was calculated as weight/
(height $ height) and expressed in kg/m2. Patients were clas-
siﬁed as normal weight (BMI range <25 kg/m2), pre-obese
(25 to 30 kg/m2), and obese (>30 kg/m2), according to
existing guidelines (14). Type 2 diabetes was deﬁned (and
treated) according to standard guidelines (12,18).Systemic hypertension was diagnosed based on resting
blood pressure values >140/90 mm Hg on 3 different
examinations and treated medically to optimize blood
pressure control, as per standard international guidelines
(18). All patients with hypertension had a diagnosis
of HCM based on 1 or more of the following criteria: 1)
HCM-causing sarcomere gene mutation or family history
of HCM; 2) onset of hypertension occurring years after the
diagnosis of HCM; 3) maximum LV wall thickness ex-
ceeding that expected by hypertension alone (i.e., >20 mm);
4) presence of marked mitral leaﬂet elongation (19); 5)
dynamic LV outﬂow obstruction (30 mm Hg) under
resting conditions (20); and 6) distribution of LGE by
contrast CMR consistent with HCM (i.e., preferentially
mid-wall or transmural, and not conﬁned to a single
coronary vascular territory) (3,5,21).
Echocardiography. Echocardiographic studies were per-
formed with commercially available instruments. Left
ventricular hypertrophy was assessed with 2-dimensional
echocardiography, and the site and extent of maximal wall
thickness were identiﬁed. Maximal end-diastolic LV wall
thickness was taken as the dimension of greatest magnitude
at any site within the chamber. Left ventricular outﬂow
obstruction, due to mitral valve systolic anterior motion and
mitral-septal contact, was identiﬁed by a peak instantaneous
outﬂow gradient 30 mm Hg occurring under basal con-
ditions (n ¼ 57) (20). Two hundred and eighteen patients
were nonobstructive at rest (basal gradient <30 mm Hg), of
whom 105 (age 43  13 years, 72% males) underwent
maximal symptom-limited exercise echocardiography, as
previously described (18); 50 developed dynamic
gradients 30 mm Hg during effort or recovery (range 48 to
155 mm Hg), and were considered to have provokable
outﬂow obstruction (20).
CMR. All CMR examinations were performed using
commercially available scanners (Philips ACS-NT 1.5-T
Gyroscan-Intera, Best, the Netherlands) and a commercial
cardiac coil. Electrocardiographic gated, steady-state, free
precession breath-hold cines in sequential 10-mm short-axis
slices (no gap) were acquired starting parallel to the atrio-
ventricular ring and covering the entire ventricle. Left
ventricular end-diastolic and end-systolic volumes, left
ventricular mass and wall thickness were calculated with
commercially available work stations (View Forum, Philips
Medical System, Best, the Netherlands) (19,21).
For calculation of LV mass, the endocardial and epicardial
borders of the left ventricle were manually planimetered on
successive short-axis cine images at end-diastole. The most
basal slice at end-diastole was visually inspected and, if
ventricular myocardium was present, it was planimetered
and included in the mass calculation. If myocardium but no
intracavitary blood pool was present on the most apical slice,
it was included in the mass calculation by planimetering only
the epicardial border. Particular care was taken to avoid
including papillary muscles in the LV mass calculation.
Left ventricular mass was derived by the summation of
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451discs method and multiplying myocardial muscle volume
by 1.05 g/cm3 (21). Left ventricular mass was indexed to
body surface area. Maximum end-diastolic LV wall thick-
ness was taken as the dimension of greatest magnitude at
any site within the LV wall. CMR measurements were
performed by an experienced investigator at each center,
blinded to the results of echocardiography. The presence of
LGE was assessed by visual inspection 15 min after intra-
venous administration of 0.2 mmol/kg gadolinium-
diethylenetriaminepentaacetic acid (Magnevist, Schering,
Berlin, Germany) with breath-held segmented inversion-
recovery sequence (inversion time 240 to 300 ms), which
was acquired in the same views as the cine images (21).
Statistical methods. Continuous variables were expressed as
mean SD, or median or interquartile range, as appropriate.
For the comparison of normally distributed variables, we
employed Student t test and 1-way analysis of variance
followed by Bonferroni post-hoc test, as appropriate. Chi-
square test (not adjusted for multiple comparisons) was
utilized to compare noncontinuous variables expressed as
proportions; Fisher exact test was employed when 1 or more
cells in the comparison table had an expected frequency of<5.Table 1 Clinical and Echocardiographic Features of the 275 HCM Pa
Overall
Normal
BMI <25 kg
n 275 69 (25%
Male 192 (70%) 32 (46%
Age at diagnosis, yrs 43  14 41  15
Age at CMR, yrs 48  14 46  14
Body surface area, m2 1.97  0.25 1.73  0.1
BMI, kg/m2 29.1  6.1 22.3  2.
Height, m 1.71  0.12 1.68  0.0
Weight, kg 85  19 63  9
NYHA functional class at ﬁrst evaluation
I 149 (54%) 37 (54%
II 67 (24%) 19 (27%
III 15 (5%) 3 (4%)
Syncope 57 (20%) 10 (14%
Atrial ﬁbrillation 30 (11%) 4 (6%)
Hypertension 75 (27%) 8 (12%
Type II diabetes 14 (5%)
Hypercholesterolemia 84 (31%) 9 (13%
Echocardiography
Left atrial diameter, mm 44  8 42  7
LV end-diastolic diameter, mm 45  6 43  6
Maximum LV wall thickness, mm 21  5 22  6
With LV outﬂow obstruction 107 (39%) 15 (22%
Medical treatment
Beta-blockers 151 (55%) 28 (40%
Verapamil 52 (19%) 9 (13%
Amiodarone 15 (5%) 4 (6%)
Disopyramide 10 (4%) 2 (3%)
Diuretics 29 (10%) 2 (3%)
ACE inhibitors/sartans 40 (14%) 4 (6%)
Warfarin 14 (5%) 0
Values are n (%) or mean  SD. *p < 0.05 versus the other 2 groups; yp < 0.05 versus normal.
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; CMR ¼ cardiac magnetic resonance;When comparing noncontinuous variables among the 3 BMI
classes, an overall p value was obtained using theMonte Carlo
method; when the p value was<0.05, individual comparisons
between the subgroups were then assessed by cross-tabulation
analysis.
Clinical features independently associated with increased
LV mass index were assessed by multivariate logistic
regression analysis using the stepwise (forward conditional)
method. Therefore, the multivariate model was ultimately
constructed only with the variables that proved signiﬁcant at
univariate analysis. Survival was assessed by Cox propor-
tional hazards regression. The survival curve was constructed
according to the Kaplan-Meier method, and comparisons
were performed using the log-rank test; p values are 2-sided
and considered signiﬁcant when <0.05. Calculations were
performed with SPSS 12.0 software (Chicago, Illinois).Results
Prevalence of obesity. The 275 HCM patients had an
average BMI of 29.1  6.1 kg/m2, ranging from 16.2 to
49.3 kg/m2. Sixty-nine patients (25%) were in the normaltients in Relation to BMI
/m2
Pre-Obese
BMI 25–30 kg/m2
Obese
BMI >30 kg/m2 p Value
) 105 (38%) 101 (37%)
) 81 (77%) 79 (78%) <0.001
45  13 44  13 0.257
50  14 49  13 0.123
8 1.99  0.2 2.11  0.23y <0.001
1 27.4  1.4 35.4  4.8y <0.001
9 1.75  0.12y 1.68  0.14 <0.001
84  11 101  16y <0.001
) 64 (61%) 48 (47%) overall
) 22 (21%) 26 (26%) 0.183
3 (3%) 9 (9%)
) 26 (25%) 21 (21%) 0.263
12 (11%) 14 (14%) 0.248
) 29 (28%) 38 (38%) 0.001
4 (4%) 10 (10%) 0.012
) 40 (38%) 35 (35%) 0.001
44  8 46  7* 0.032
45  6 46  6* 0.025
21  5 21  5 0.272
) 41 (39%) 51 (50%)* 0.001
) 62 (59%) 61 (60%) 0.427
) 22 (21%) 21 (21%) 0.578
6 (6%) 5 (5%) 0.850
4 (4%) 4 (4%) 0.613
9 (8%) 18 (18%)* <0.001
14 (13%) 22 (21%)* <0.01
5 (5%) 9 (9%) 0.155
HCM ¼ hypertrophic cardiomyopathy; LV ¼ left ventricular; NYHA ¼ New York Heart Association.
Figure 1
Prevalence of LV Outﬂow Obstruction in
Relation to BMI
Bar graph illustrating the proportion of patients in each body mass index (BMI)
class with left ventricular outﬂow tract (LVOT) obstruction (30 mm Hg) at rest or
with exercise. Increase in BMI is associated with greater likelihood of an
obstructive pathophysiology. *p < 0.05 versus normal weight. yp < 0.05 versus
pre-obese.
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452weight range (BMI <25 kg/m2; average 22.3  2.1),
105 (38%) were pre-obese (BMI 25 to 30 kg/m2; average
27.4  1.4), and 101 (37%) were obese (BMI >30 kg/m2;
average 35.4  4.8) (Table 1). Overall, 107 patients (39%)
were found to have LV outﬂow obstruction (i.e., a peak
instantaneous outﬂow gradient 30 mm Hg) occurring
either under basal conditions (n ¼ 57) or during physiologic
exercise (n ¼ 50). Seventy-ﬁve patients (27%) had a history
of controlled systemic hypertension and 14 (5%) had adult-
onset, type II diabetes. Left ventricular outﬂow obstruction,
both under resting conditions and elicited by exercise, was
disproportionally prevalent in pre-obese and obese patients
(Fig. 1, Table 1). Likewise, systemic hypertension and dia-
betes were more prevalent in pre-obese and obese comparedTable 2 Cardiovascular Magnetic Imaging Findings in 275 HCM Pat
Overall
Normal
BMI <25 kg/m2
n 275 69 (25%)
LV end-diastolic volume, ml 151  45 115  29
LV end-systolic volume, ml 43  22 33  17
LV ejection fraction, % 72  10 71  11
Stroke volume, ml 108  33 82  23
Mass/volume ratio 1.3  0.5 1.3  0.5
Patients with LGE 125 (46%) 19 (28%)
LGE mass, g 10.4 (6.2–26.6) 14.4 (9.2–50.7)
LGE percent of LV volume 2.8 (1.8–6.5) 3.4 (1.8–12.1)
Values are n (%), mean  SD, or median (interquartile range). *p < 0.05 versus normal. yp < 0.05 ver
LGE ¼ late gadolinium enhancement; other abbreviations as in Table 1.with normal weight patients (Table 1); 38 of the 101 obese
HCM patients (38%) were also hypertensive.
Relation of BMI to LV mass, volume, and function. Av-
erage LV mass index in the HCM patient cohort was 104 
40 g/m2, ranging from 41 to 329 g/m2 (highest quartile
cutoff 120 g/m2), greater in males (109  41 g/m2 vs. 91 
36 in females, p < 0.001) (Table 2). Compared with normal
weight patients, LV mass index progressively increased in
pre-obese and obese patients: 95  46 g/m2, 100  31 g/m2,
and 114  43 g/m2, respectively (overall p ¼ 0.005; obese
patients p < 0.05 vs. each other group) (Fig. 2), reﬂecting
a direct relationship between LV mass and BMI (correlation
coefﬁcient ¼ 0.23; p < 0.001). Thus, obesity in HCM
patients was associated with a 120% increase in indexed
LV mass, compared with normal body weight. Conversely,
maximum LV wall thickness was virtually identical in
normal weight, pre-obese, and obese patients (22  6 mm,
21  5 mm, and 21  5 mm, respectively; p ¼ 0.27).
Increased LV mass with respect to body weight was
associated with higher LV end-diastolic volume index: 66 
14 ml/m2 in normal weight, 77  18 ml/m2 in pre-obese,
and 83  20 ml/m2 in obese patients (overall p < 0.001)
(Figs. 3 and 4). Therefore, obese patients showed a 126%
increase in indexed LV cavity size compared with those of
normal weight. Nevertheless, average LV end-diastolic
dimension remained within the normal range for each
group (i.e., nondilated LV cavity) (Table 2). Notably, when
the subset of 168 nonobstructive HCM patients was
analyzed separately, the direct correlation of BMI and
LV mass index persisted (correlation coefﬁcient 0.22,
p ¼ 0.004).
Conversely, LV systolic function, as expressed by ejection
fraction, did not differ among the 3 BMI classes (p ¼ 0.86);
by virtue of greater end-diastolic volumes, stroke volume
index increased from normal weight to pre-obese to obese
HCM patients, whereas mass/volume ratio was unchanged
(Table 2). Prevalence of LGE was increased in pre-obese
and obese HCM patients (48% and 55%, respectively)
compared with the normal weight patients (28%, overall
p ¼ 0.001). However, average %LV mass occupied by LGEients With Respect to BMI
Pre-Obese
BMI 25–30 kg/m2
Obese
BMI >30 kg/m2 p Value
105 (38%) 101 (37%)
154  38* 174  45y <0.001
44  23* 49  25* <0.001
72  10 72  9 0.864
109  28* 125  34y <0.001
1.3  0.4 1.4  0.5 0.428
50 (48%)* 55 (55%)* 0.001
15.6 (5.6–26.1) 9.5 (4.7–21.2) 0.240
2.9 (1.9–7.3) 2.3 (1.5–5.2) 0.552
sus each of the other 2 groups.
Figure 2 Impact of BMI on LV Mass
Each panel shows mean (95% conﬁdence interval for mean) for unadjusted LV
mass and LV mass index in each of the 3 BMI classes. Overall p value for
hypertrophic cardiomyopathy patients was 0.005 (obese patients p < 0.05 vs.
each of the other 2 groups). *p < 0.05 versus normal weight; yp < 0.05 versus
Pre-Obese. Wt ¼ weight; other abbreviations as in Figure 1.
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453in individual patients did not differ between the subgroups
(overall p ¼ 0.55) (Table 2).
Systemic hypertension was associated with increased LV
mass index in our HCM cohort (118  44 g/m2 vs. 98 
36 g/m2 in normotensive; p < 0.001), although type 2 dia-
betes was not (LV mass index 104  41 g/m2 vs. 104 
21 g/m2 in nondiabetic patients; p ¼ 0.98). Patients who
were both obese and hypertensive hadLVmass index values of
126 44 g/m2, comparedwith 93 42 g/m2 in those patients
who were neither obese nor hypertensive (p < 0.001).
Correlates of LV mass. A multivariate regression model
was constructed to identify variables independently associ-
ated with greater magnitude of LVH, deﬁned by an LV mass
in the highest quartile for the overall cohort, or >120 g/m2.
Variables assessed included BMI, age, sex, resting, or pro-
vokable LV outﬂow obstruction, systemic hypertension, andtype 2 diabetes. The model was ultimately constructed with
the 3 variables that proved signiﬁcant at univariate analysis
(i.e., obesity, sex, and LV outﬂow obstruction). In this
model, BMI proved an independent correlate of LV mass
>120 g/m2, with a hazard ratio (HR) per unit increase of
1.07 (95% CI: 1.01 to 1.13; p ¼ 0.019).
Pre-obese HCM patients showed a 65% increased like-
lihood of assignment to the highest LV mass index quartile,
compared with normal weight patients (HR: 1.65; 95% CI:
0.73 to 3.74; p ¼ 0.22), while in obese patients this likeli-
hood increased >300% (HR: 3.1; 95% CI: 1.42 to 6.86;
p ¼ 0.004). Other variables associated with LV mass >120
g/m2 were resting or provokable outﬂow obstruction (HR:
4.9; 95% CI: 2.4 to 9.8; p < 0.001), systemic hypertension
(HR: 2.2; 95% CI: 1.1 to 4.5; p ¼ 0.026), and male sex
(HR: 2.1; 95% CI: 0.9 to 4.7; p ¼ 0.08).
Symptomatic status and outcome. During a median
follow-up of 3.7 years (interquartile range: 2.5 to 5.3 years)
following CMR, there were 25 deaths (or equivalents), of
which 6 were noncardiac and 19 were HCM-related. Of the
latter 19 death events, 12 were sudden (including 7 deaths,
2 patients resuscitated from cardiac arrest, and 3 appropriate
implantable cardioverter-deﬁbrillator discharges for ventric-
ular tachycardia/ﬁbrillation). In addition, there were 6 heart
failure–related events (3 deaths and 3 heart transplants), and
1 post-operative death (surgical septal myectomy). There
was no difference in all-cause mortality among the 3 BMI
classes (Fig. 5).
In the 256 patients who were alive at the end of follow-
up, those with obesity were however more likely to have
developed progressive New York Heart Association
(NYHA) functional class III to IV symptoms at most recent
evaluation, compared with normal weight patients (overall
p ¼ 0.027). Noticeably, the proportion of patients in NYHA
functional class III at the end of follow-up was 13% among
obese patients, compared with 6% among those of normal
weight (p ¼ 0.03) (Fig. 5). Independent predictors of
NYHA functional class III to IV symptoms at end of
follow-up were obesity (HR: 3.6; 95% CI: 1.2 to 10.7;
p ¼ 0.02), female sex (HR: 4.3; 95% CI: 1.5 to 12.4;
p ¼ 0.007), and LV outﬂow obstruction (HR: 2.7; 95% CI:
0.9 to 7.8; p ¼ 0.07), whereas age, history of atrial ﬁbrilla-
tion, and hypertension were not.Discussion
Obesity and the HCM phenotype. In HCM, the primary
morphologic expression of LVH has historically been
considered solely a consequence of the gene mutation, with
no evidence to date that environmental variables can inﬂu-
ence phenotypic expression (2,5,7,8). However, the extreme
heterogeneity of phenotypic expression among HCM
patients, even in family members sharing the same mutation
(6), implies that other determinants of cardiac morphology
must be operative (2,3–5). For example, greater LV mass has
been observed in male patients and those with dynamic LV
Figure 3 Cardiac Remodeling in an Obese Patient With Hypertrophic Cardiomyopathy
Images from a 35-year-old male patient with a body mass index of 28 kg/m2. Left ventricular mass was 367 g (indexed 153 g/m2), with a maximal wall thickness of 29 mm.
Left ventricular end-diastolic volume was 235 ml (indexed 97 ml/m2) and left ventricular ejection fraction was 80%. (A) Cardiac magnetic resonance steady state free
precession 4-chamber showing diffuse thickening with sparing of the apex. (B) Corresponding late gadolinium enhancement imaging shows lack of ﬁbrosis in LV.
*Subcutaneous fat, Dintrathoracic visceral fat. LA ¼ left atrium; LV ¼ left ventricle; RA ¼ right atrium; RV ¼ right ventricle.
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454outﬂow obstruction (21), suggesting the disease phenotype
may be sensitive to environmental modulation (22). In order
to address this issue, we have considered whether obesity, an
established cardiovascular risk factor known to promote
LVH in the general population, may inﬂuence the magni-
tude of LV mass and prognosis in a multicenter HCM
cohort.
Our data demonstrate that obesity is independently
associated with increased LV mass, establishing a novel
principle that environmental variables can inﬂuence disease
expression in a primary genetic cardiomyopathy such as
HCM, a concept also relevant to other cardiomyopathies
(22). Indeed, BMI was powerfully associated with severe LV
mass increase in our HCM patients, independent of other
important determinants such as sex and dynamic LV
outﬂow obstruction (21), as well as systemic hypertension
(18). In our HCM patients, the relationship between BMIFigure 4 Impact of BMI on LV Volume and Function
Panels show mean (95% conﬁdence interval for mean) LV end-diastolic volume index, LV
each variable are provided in Table 1. *p < 0.05 versus normal weight; yp < 0.05 versuand LV mass became particularly evident for BMI values
>30. Obese patients were >3 times as likely to have
a marked increase in LV mass exceeding 120 g/m2,
compared with those of normal weight. This increase in LV
mass was driven primarily by greater end-diastolic volume
(which nevertheless remained within normal limits when
indexed to body size). In the general population, LV
remodeling associated with chamber enlargement is an
established consequence of obesity, which normalizes stroke
volume index in the presence of increased oxygen require-
ment, thereby reﬂecting a physiologic adaptation to body
weight (14,15,17,23,24). This principle was also supported
by our observation that greater LV cavity volume in obese
HCM patients was accompanied by preserved systolic
function, resulting in an increased stroke volume index
(14,15,23,24). Such impact of obesity on the HCM
phenotype is likely mediated by the same triggers producingejection fraction, and stroke volume index for the 3 BMI classes. Overall p values for
s pre-obese. Wt ¼ weight; other abbreviations as in Figure 1.
Figure 5 Impact of BMI on Survival
Cumulative risk of all-cause mortality in normal weight, pre-obese, and obese
patients during follow-up (top). Prevalence of HCM-related mortality and severe
heart failure symptoms (NYHA functional classes III or IV) among survivors at the
end of follow-up period (bottom). *p ¼ 0.03 versus other 2 groups. CMR ¼ cardiac
magnetic resonance; HCM ¼ hypertrophic cardiomyopathy; NYHA ¼ New York
Heart Association; Wt ¼ weight.
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455increased LV mass in obese individuals without HCM, via
the hemodynamic and neurohormonal pathways of sec-
ondary hypertrophy (17). The alternative hypothesis that
excess body weight may directly act upon the primary
etiology of HCM (e.g., by acting as a genetic modiﬁer upon
disease-causing sarcomere genes) cannot be excluded but
appears much less plausible (22).
Notably, absolute LV wall thickness was unaffected by
body weight, with obese patients showing maximum
thickness values virtually identical to those in patients of
normal weight. This observation suggests that the 2 features,
which most differentiate HCM from secondary forms of
LVH (i.e., the asymmetric distribution of LV thickening
and the often marked degree of regional hypertrophy) are
largely unaffected by environmental modulation (4,7).
Therefore, neither the current clinical diagnostic criteria for
HCM nor decision-making for primary prevention of
sudden death with implantable cardioverter-deﬁbrillators
(both based on maximum absolute LV wall thickness)
(1,3,25–27) require adjustment with respect to BMI in adultpatients. In addition, our ﬁndings emphasize the importance
of assessing total LV mass (by CMR), rather than maximum
LV wall thickness, in order to evaluate environmental in-
ﬂuences on the HCM phenotype (21). In the present study,
for example, mere evaluation of maximum LV thickness in
the 3 BMI subgroups would have overlooked the impact of
excess body weight on the total hypertrophic burden of our
patients.
Obesity and symptomatic status/outcome. During an
average follow-up of almost 5 years, obese HCM patients had
a 3.6-fold increased risk of developing severe functional
limitation (NYHA functional class III/IV) compared with
non-obese patients, independent of other known determi-
nants of heart failure symptoms such as outﬂow obstruction
(28) and atrial ﬁbrillation (26). It is impossible to ascertain
precisely what proportion of functional limitation was due
directly to obesity, as opposed to the consequences of HCM
disease state (1,3). Nevertheless, symptomatic obese patients
showedno impairment inLV ejection fraction, indicating that
their severe disease proﬁle was not due to progressive systolic
dysfunction (or “end-stage” HCM) (5). In the general pop-
ulation, obesity is an important predictor of heart failure
(12,16,18,29), associated with multiple and often profound
changes in the cardiovascular system, including increased
cardiac oxygen requirement, sympathetic and neurohormonal
activation, increased oxidative stress, increased cardiac output,
and expanded central blood volume causing hemodynamic
overload in the face of reduced cardiac efﬁciency (17,29–31).
Likewise, our data suggest that excessive body weight in
HCM patients may impact importantly on symptom
progression, potentially triggering a cycle of events in which
obesity leads to an obligatory sedentary lifestyle, further
increases in BMI, and, ultimately, worsening of heart failure
symptoms (16). Whether signiﬁcant weight loss will lead to
reduction of symptoms and LV mass in obese HCM patients
remains unresolved, although these data support future
longitudinal studies aimed at clarifying this issue (32).
On the other hand, obesity itself did not confer an
independent survival disadvantage during follow-up in our
HCM cohort. Although the size of study population and the
small number of events does not allow deﬁnitive conclusions
in this regard, our ﬁndings do suggest that other clinical
variables may be more relevant than body weight in deter-
mining survival in this complex disease (3,5,28), consistent
with the elusive relationship of body weight to outcome in
cardiovascular disease at large (29,30). Indeed, while obesity
is associated with increased morbidity and mortality in the
general population (9,13,16,29), a high BMI represents
a strong independent predictor of favorable outcome in
patients with chronic heart failure, a phenomenon known as
the “obesity paradox” (30).
Signiﬁcance of LV outﬂow obstruction and hypertension.
Left ventricular outﬂow obstruction was >2-fold more
prevalent in obese HCM patients compared with those of
normal weight, and associated with a further increase in LV
mass (20,21). Although the mechanisms accounting for this
Olivotto et al. JACC Vol. 62, No. 5, 2013
Obesity and LV Mass in Hypertrophic Cardiomyopathy July 30, 2013:449–57
456relationship are uncertain, the abnormally increased adren-
ergic drive associated with obesity may predispose to
development of intraventricular gradients (31). Such obser-
vations may suggest that excess LVH in obese patients is
principally mediated by outﬂow obstruction and afterload
mismatch (21). Nevertheless, when the present analysis was
restricted to nonobstructive HCM patients, the association
between BMI and LV mass persisted, consistent with the
concept that cardiac remodeling due to excess body weight is
largely independent of (although synergistic to) outﬂow
obstruction (14,21). We acknowledge that the overall
prevalence of LV outﬂow obstruction in the present cohort
(39%) was signiﬁcantly lower than that reported in a pre-
vious study by our group (i.e., 70%) (20). This is largely due
to the fact that, in the quoted study, all patients without
resting obstruction at baseline were systematically exercised
in order to assess provokable obstruction (20), whereas only
105 of 218 such patients were assessed during exercise in the
present cohort. Therefore, the true prevalence of obstruction
elicited by physiological exercise may have been under-
estimated in our study.
Systemic hypertension was another modiﬁer of the HCM
phenotype (9,13). As expected, the prevalence of elevated
blood pressure increased with body weight, and was present
in almost 40% of obese patients in our HCM cohort. Even
though pharmacologically treated according to existing
guidelines (18), hypertension doubled the likelihood of
severe LVH in these patients, independent of other deter-
minants of LV mass. Furthermore, the combination of
obesity and hypertension was associated with the highest LV
mass values observed for any subset within the cohort. Thus,
the present ﬁndings support the concept that the neuro-
hormonal abnormalities associated with hypertension may
impact LV mass in HCM patients (16,23,33), and thereby
represent a relevant therapeutic target (16,18). To this
regard, it is important to acknowledge that environmental
inﬂuences of single cardiovascular risk factors on the HCM
phenotype are unavoidably linked to a number of coexisting
factors (22). For example, obesity is per se associated with an
increased likelihood of hypertension, diabetes, and dynamic
LV outﬂow obstruction (11,16). Therefore, interpretation of
the clinical role of each of these factors, in isolation from the
overall pathophysiological picture, remains challenging.Conclusions
The present study provides evidence that obesity is inde-
pendently associated with adverse cardiac remodeling and
increase in LV mass in HCM patients. These observations
underscore the novel principle that the primary phenotypic
expression in this complex, heterogenous heart disease is also
subject to environmental variables and not solely the product
of disease-causing sarcomere mutations. In addition, obesity
appears to play a role in the development and progression of
heart failure symptoms in HCM, supporting the need forfollow-up studies clarifying whether modulating obesity can
improve clinical course.Reprint requests and correspondence: Dr. Iacopo Olivotto,
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